Advancements in understanding tumor biology, identifying predictive biomarkers, and developing targeted therapies have ...

At the San Antonio Breast Cancer Symposium, researchers presented findings on Clarity BCR, a multimodal multitask ...

EPIK-B5 study evaluated alpelisib plus fulvestrant vs placebo for efficacy and safety in patients with PIK3CA-m HR+, HER2− advanced breast cancer who had progressed on a CDK4/6 inhibitor and an ...

As clinical research evolves, disruptive trial designs are reshaping how oncology advances. By integrating novel ...

Eli Lilly and Co shared updated results of Inluriyo (imlunestrant) from a Phase 3 study in previously treated breast cancer patients.

ctDNA offers a minimally invasive alternative for detecting PIK3CA, AKT1, and PTEN alterations in hormone receptor-positive breast cancer when tissue is unavailable. The CAPItello-291 trial showed ...

Based on the primary PFS analysis of EMBER-3, the FDA approved single-agent imlunestrant in September 2025 for the treatment of patients with ER+/HER2– ESR1 m advanced breast cancer with disease ...

Scientists warn that the human Y chromosome has lost most of its genes over millions of years, and new research suggests ...

Atossa Therapeutics, Inc. ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of high unmet need, presented four ...

A large genomic study shows that 14 major psychiatric disorders share strong genetic overlap, grouping into five biological ...

Athira has acquired an exclusive global license (excluding Asia and certain countries in the Middle East) from Sermonix Pharmaceuticals, Inc. for rights to develop and commercialize lasofoxifene, a ...

Eli Lilly (LLY) and Company announced updated results from the Phase 3 EMBER-3 study of Inluriyo, an oral estrogen receptor antagonist, in ...